Novartis Ag (NVS) Debt to Equity (2017 - 2025)
Novartis Ag's Debt to Equity history spans 9 years, with the latest figure at $0.62 for Q4 2025.
- For Q4 2025, Debt to Equity fell 8.16% year-over-year to $0.62; the TTM value through Dec 2025 reached $0.62, down 8.16%, while the annual FY2025 figure was $0.62, 8.16% down from the prior year.
- Debt to Equity for Q4 2025 was $0.62 at Novartis Ag, down from $0.67 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.67 in Q4 2024 and bottomed at $0.36 in Q4 2022.
- The 5-year median for Debt to Equity is $0.41 (2023), against an average of $0.49.
- The largest annual shift saw Debt to Equity surged 100.06% in 2021 before it decreased 8.16% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.38 in 2021, then decreased by 5.61% to $0.36 in 2022, then increased by 14.78% to $0.41 in 2023, then skyrocketed by 64.82% to $0.67 in 2024, then decreased by 8.16% to $0.62 in 2025.
- Per Business Quant, the three most recent readings for NVS's Debt to Equity are $0.62 (Q4 2025), $0.67 (Q4 2024), and $0.41 (Q4 2023).